Objectives: This study investigated changes in health-related quality of life (QOL) in patients treated for pararenal (PRA) and thoracoabdominal aortic aneurysms (TAAAs) with fenestrated-branched endovascular aortic repair (F-BEVAR).
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Clinical Trial and Real-World Outcomes of Endovascular Iliac Aneurysm Repair With the Gore Iliac Branch Endoprosthesis (IBE)
Objectives: The purpose of this study was to determine the midterm effectiveness of endovascular iliac artery aneurysm repair with hypogastric artery preservation using the Iliac Branch Endoprosthesis (IBE; W. L. Gore, Flagstaff, Ariz) in both multicenter trial and "real-world" use settings.
Methods: All patients who underwent treatment of iliac artery aneurysms with the IBE device as subjects in the pivotal IBE 12-04 prospective United States multicenter study and the Global Registry for Endovascular Aortic Treatment (GREAT) prospective multicenter international registry study between 2013 and 2015 were included. Pooled and side-by-side comparisons of outcomes through 3 years of follow-up were analyzed. Data were analyzed for procedural success, overall survival, iliac patency, reinterventions, and incidence of new-onset buttock claudication or sexual dysfunction.
Results: A total of 190 patients underwent treatment with 207 IBE device (s), including 98 patients in IBE 12-04 (pivotal study cohort, n ¼ 63; and continued access cohort, n ¼ 35) and 92 patients in GREAT. Seventeen patients (8.9%) underwent bilateral IBE device placement. The GREAT cohort included more females (n ¼ 7.6% vs n ¼ 1.0%; P ¼ .03), more nonwhites (25.9% vs 11.1%; P < .001), and the patients were older (mean age, 72.7 6 7.7 vs 69.0 6 9.3 years; P < .011) than in the IBE 12-04 cohort. However, mean common iliac aneurysm diameters were similar (IBE 12-04: 39.3 6 10.9 mm; GREAT: 36.6 6 11.0 mm). In GREAT, 62% of were treated outside of instructions for use guidelines and would not have met inclusion/exclusion criteria for the IBE 12-4 study. Procedural survival was 100% in both cohorts. Mean follow-up was 537 days for IBE 12-04 and 225 days for GREAT. All-cause mortality was 6.1% in IBE 12-04 and 5.4% in GREAT. Device-related reinterventions occurred in 8.2% for IBE 12-04 and 4.3% for GREAT. The incidence of hypogastric or external iliac artery occlusion was 8.2% for IBE 12-04 and 1.1% for GREAT, with 
